With FedRAMP® High authorization, Ceribell’s secure, cloud-based solution can be adopted across federal healthcare systems, ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of ...

With this integration, clinicians using Haiku can now leverage Commure’s AI-driven ambient documentation capabilities, reducing administrative burdens and allowing them to focus more on patient care – ...

The Constant Therapy platform’s UK English and Australian English editions will also be available in June 2025. Spanish speakers and Indian English speakers can access 1 Million+ exercises, developed ...

Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at ...

Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Presenter: Joanne ...

Cidara will also participate in one-on-one investor meetings during this event.

Institutional investors interested in meeting with management during the conference may reach out to their Citizens representative.

KIRKLAND, Wash., April 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to participate in the ...

SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation ...

The webcast of the presentation will be accessible in the Investor section of the Actuate website. The Actuate management team will participate in one-on-one investor meetings during this event.

Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free survival (PFS) in Phase 3 patients ...